Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-05-20 | Direct | 41,800 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 41,800 · Balance 41,800 F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2: Options to vest 100% on May 20, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 34,200 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 34,200 · Balance 34,200 F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.
F2: Options to vest 100% on May 20, 2027.
F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 21, 2026 20:11 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 34,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001669080-26-000003 · wk-form4_1779394282.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,200 Underlying: Common Stock · 34,200 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:11 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 41,800 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001669080-26-000003 · wk-form4_1779394282.xml · derivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,800 Underlying: Common Stock · 41,800 shares Expires 2036-05-20 F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 20, 2027. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 972 | $0.00 | $0.00 |
DisclosureSEC source: 0001669080-26-000002 · wk-form4_1772228657.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units granted on February 27, 2023 was as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares vested on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units granted on February 27, 2023 was as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares vested on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units granted on February 27, 2023 was as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares vested on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001669080-26-000002 · wk-form4_1772228657.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units granted on February 27, 2023 was as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares vested on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 21, 2025 Filed May 21, 2025 20:57 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000032 · wk-form4_1747861024.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. Read SEC document |
| May 21, 2025 Filed May 21, 2025 20:57 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000032 · wk-form4_1747861024.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 972 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000001 · wk-form4_1740783911.xml · derivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 972 Underlying: Common Stock · 972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 972 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000001 · wk-form4_1740783911.xml · derivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000001 · wk-form4_1740783911.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000001 · wk-form4_1740783911.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 21, 2024 Filed May 22, 2024 20:51 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 2,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000038 · wk-form4_1716411039.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,167 Underlying: Common Stock · 2,167 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025. Read SEC document |
| May 21, 2024 Filed May 22, 2024 20:51 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 2,917 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001055726-24-000038 · wk-form4_1716411039.xml · derivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,917 Underlying: Common Stock · 2,917 shares Expires 2034-05-21 F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: Options to vest 100% on May 21, 2025. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 2,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000028 · wk-form4_1715893516.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 2,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000028 · wk-form4_1715893516.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 972 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · derivative · entry 6 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,944 Underlying: Common Stock · 972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares will vest on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares will vest on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares will vest on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 972 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · derivative · entry 5 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 972 Underlying: Common Stock · 972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 972 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · derivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units was as follows: 972 shares vested on February 26, 2022; 972 shares vested on February 26, 2023; and 972 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units was as follows: 972 shares vested on February 26, 2022; 972 shares vested on February 26, 2023; and 972 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units was as follows: 972 shares vested on February 26, 2022; 972 shares vested on February 26, 2023; and 972 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · nonDerivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares will vest on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units was as follows: 972 shares vested on February 26, 2022; 972 shares vested on February 26, 2023; and 972 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 16, 2023 Filed May 16, 2023 20:54 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000037 · wk-form4_1684270484.xml · derivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. Read SEC document |
| May 16, 2023 Filed May 16, 2023 20:54 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 19,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000037 · wk-form4_1684270484.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 929,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:54 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000037 · wk-form4_1684270484.xml · derivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units will vest 100% on May 15, 2024. F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units will vest 100% on May 15, 2024. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units will vest 100% on May 15, 2024. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:54 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 35,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001055726-23-000037 · wk-form4_1684270484.xml · derivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-05-15 F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Options to vest 100% on May 15, 2024. Read SEC document |
| March 13, 2023 Filed Mar 13, 2023 21:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 5,833 | $1.15 | $6,707.95 |
DisclosureSEC source: 0001055726-23-000014 · wf-form4_167874179632291.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910,124 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 13, 2022. Read SEC document |
| March 11, 2023 Filed Mar 13, 2023 21:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000014 · wf-form4_167874179632291.xml · derivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; and 11,666 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; and 11,666 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; and 11,666 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2023 Filed Mar 13, 2023 21:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000014 · wf-form4_167874179632291.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; and 11,666 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · derivative · entry 7 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 27, 2023, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares will vest on February 26, 2024; 11,667 shares will vest on February 26, 2025; and 11,666 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 27, 2023, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares will vest on February 26, 2024; 11,667 shares will vest on February 26, 2025; and 11,666 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 27, 2023, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares will vest on February 26, 2024; 11,667 shares will vest on February 26, 2025; and 11,666 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 60,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · derivative · entry 6 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-02-27 F4 · derivative.exercise_date: The vesting schedule for the 60,000 options is as follows: 15,000 shares vested on February 27, 2023; 15,000 shares will vest on February 26, 2024; 15,000 shares will vest on February 26, 2025; and 15,000 shares will vest on February 26, 2026. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 11,668 | $1.28 | $14,935.04 |
DisclosureSEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · nonDerivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,291 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 13, 2022. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · derivative · entry 5 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,333 Underlying: Common Stock · 11,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · derivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,666 Underlying: Common Stock · 11,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| August 11, 2022 Filed Aug 11, 2022 20:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 11,875 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001055726-22-000050 · wf-form4_166024891625374.xml · derivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,875 Underlying: Common Stock · 11,875 shares Expires 2023-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · balance_after: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| August 11, 2022 Filed Aug 11, 2022 20:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 11,875 | $2.66 | $31,587.50 |
DisclosureSEC source: 0001055726-22-000050 · wf-form4_166024891625374.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892,625 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $2.66 to $2.69, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 11, 2022 Filed Aug 11, 2022 20:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,875 | $2.16 | $25,650.00 |
DisclosureSEC source: 0001055726-22-000050 · wf-form4_166024891625374.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 28,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001055726-22-000041 · wf-form4_165281944451001.xml · derivative · entry 5 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2032-05-16 F4 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F5 · derivative.exercise_date: Options to vest 100% on May 16, 2023. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000041 · wf-form4_165281944451001.xml · derivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. F4 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 9,000 | $1.95 | $17,550.00 |
DisclosureSEC source: 0001055726-22-000041 · wf-form4_165281944451001.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892,625 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer. Read SEC document |
| May 13, 2022 Filed May 17, 2022 20:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000041 · wf-form4_165281944451001.xml · derivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. Read SEC document |
| May 13, 2022 Filed May 17, 2022 20:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000041 · wf-form4_165281944451001.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. Read SEC document |
| March 14, 2022 Filed Mar 14, 2022 20:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 4,083 | $3.20 | $13,065.60 |
DisclosureSEC source: 0001055726-22-000021 · wf-form4_164729029489063.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 883,625 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer. F3 · price: These transactions were executed in multiple trades at prices ranging from $3.19 to $3.23, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000021 · wf-form4_164729029489063.xml · derivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,666 Underlying: Common Stock · 11,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000021 · wf-form4_164729029489063.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2022 Filed Mar 9, 2022 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 4,083 | $3.33 | $13,596.39 |
DisclosureSEC source: 0001055726-22-000014 · wf-form4_164685990756495.xml · nonDerivative · entry 2 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 876,041 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 11,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000014 · wf-form4_164685990756495.xml · derivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000014 · wf-form4_164685990756495.xml · nonDerivative · entry 1 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:51 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000013 · wf-form4_164617866156651.xml · derivative · entry 4 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2023; 11,667 shares will vest on February 26, 2024; 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2023; 11,667 shares will vest on February 26, 2024; 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2023; 11,667 shares will vest on February 26, 2024; 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2023; 11,667 shares will vest on February 26, 2024; 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:51 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 60,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001055726-22-000013 · wf-form4_164617866156651.xml · derivative · entry 3 Weiner David B. · CIK 0001669080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-02-26 F2 · derivative.exercise_date: The vesting schedule for the 60,000 options is as follows: 15,000 shares vested on February 26, 2022; 15,000 shares will vest on February 26, 2023; 15,000 shares will vest on February 26, 2024; 15,000 shares will vest on February 26, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.